Role of PAI-1 in Pediatric Obesity and Nonalcoholic Fatty Liver Disease

AbstractPurpose of ReviewThe purpose of this study is to review the role of plasminogen activator inhibitor-1 (PAI-1) in pediatric obesity and nonalcoholic fatty liver disease (NAFLD).Recent FindingsOngoing evidence supports that patients with insulin resistance, obesity, NAFLD, and cardiovascular disease have higher levels of PAI-1. The role of PAI-1 in NAFLD has been further delineated and both experimental models and human studies strongly support an independent role of PAI-1 in the pathophysiology of NAFLD.SummaryGrowing evidence supports a mechanistic role of PAI-1 in obesity associated metabolic abnormalities including NAFLD and its long-term association with CVD. Reduction of PAI-1 could be a promising therapeutic strategy for both ongoing hepatic injury and reduction of associated cardiovascular risk.

Source: Current Cardiovascular Risk Reports - February 28, 2017 Category: Cardiology Source Type: research